Livdelzi says fellversprechende Ergebnisse in PBC-Behandlungsstudie Von Investing.com

FOSTER CITY, California – Gilead (NASDAQ:) Sciences, Inc. (NASDAQ:GILD) has unveiled the most advanced Phase 3 ASSURE trial. This opinion, that 81% of treated patients with primary cholangitis (PBC) have had an amalgamation of biochemical studies. Die auf dem Liver Meeting 2024 ensured that the data contained 41% of the normal alkaline phosphatase (ALP) value, a certain marker for liver function.

The ASSURE study investigates the long history and security of life when researching with PBC, the research into Ursodeoxycholsäure (UDCA) is no longer possible. Zum Stichtag 31.01.2024 has finished analyzing all parts of the ASSURE study. It is a fact that there is no question of an unacceptable Ereignisse in the Zusammenhang mit der Behandlung reportedet, and the Häufigkeit unerwünschter Ereignisse nahm in Laufe der Zeit ab.

Dr. Eric J. Lawitz, principal investigator of the study, concretes the Bedeutung of the ALP standard in PBC management and the potential of life support as a possible treatment option for patients.

Gilead presenterte auch Ergebnisse der RESPONSE-Studie, die die Wirksamkeit und Sicherheit von Livdelzi in PBC-Patients met zirrosis compensator die die in die Schweregrad van de Juckreizes revorhob. The RESPONSE study is a pivotal phase 3 study, which as a double-blind, placebo-controlled clinical trial makes research and life assurance possible.

Leven is an oral PPAR-delta agonist and the first treatment, the statistically significant and long-lasting changes that occur as the marker of cholestasis in pregnancy with the risks of a certain progressive progression. The drug was released in August 2024 and has been submitted to the US Food and Drug Administration (FDA) for the treatment of PBC in combination with UDCA or as a monotherapy for patients, the UDCA is not possible.

If you view some of the data in one of the following ways, you will analyze the live programs, which will show the view of the medications if you don’t want to wait another year.

Gilead can increase involvement, therapies for swinging life treatments, of which the philosophy of life is part of the treatment, the unsatisfactory beds of PBC patients being treated. The information shown is based on a Gilead Sciences, Inc. press conference.

In other cases, Gilead Sciences received a Kaufempfehlung from Citi with a Kursziel of 125 US dollars. This positive assessment is based on the erwarteten Wachstum of Gilead’s HIV-Treatment Biktarvy and the potency of the recommended medication Lenacapavir. Citi’s analysis is based on Gilead on a long-term basis and forecasts 5-year revenue and non-GAAP earnings for action (EPS) with a high waiting rate (CAGR) of 3% bzw. 18% from 2024 to 2029.

Darüber hinaus gab Gilead seine Ergebnisse für das dritte Quartal 2024 bekannt. In the conference call of the Ergebnissen, former directors and CEO Daniel O’Day challenged the rule of the winners’ war, which focused on Gilead’s poor performance. The Einzelheiten dieser Erwartungen wurden allthings nietengelegt.

The forecast of poor cooperation with Marge’s employee for Gilead, which had reached the interests of 45% of the total overload, was one of the successful results of the external business activities. Work is underway to treat Zelltherapie-Sparte until 2026 at a rate of 8%. These young companies underline Gilead’s achievements and growth potential, based on their recent achievements as well as their future experiences with Citi.

InvestingPro Insights

Gilead Sciences’ research has paid close attention to living in the treatment of primary cholangitis (PBC) in a long time with the strong market position and financial capabilities of our developing world. Laut InvestingPro-Daten paints Gilead on a beach market capitalization of 111.37 billion US dollars, was the Vertrauen der Investoren in the Pipeline and the best product portfolio of the broader mirror of the external parties.

If you have a 7.02% share in the quarter, with a robust gross margin of 77.8%, you are no longer burdened with dealing with an effective life in the market. This financial support is provided to Gileads who provide research and treatment support for Lebererkrankungen and other therapeutic areas.

InvestingPro-Tips have reformed Gileads Stabilität and Wachstumspotenzial. The relationship with the dividend 10 years in Folge erhöht was the commitment for action plans. The analysts had made a profit forecast for the expected results 15 years ago, but were positive about the Gileads financing, which may have been influenced by Entwicklungen with the Fortschritt of Livdelzi.

The Action of Gilead hat in the three months has become strong momentum, with a trend of 25.06%. This performance can support the market optimism of the pipeline’s wider mirrors, one of the Livdelzi’s capabilities in the PBC market.

It is a good idea for investors to make such analyses InvestPro 12 Other Tips for Gilead Sciences offer a huge variety of financing options and market positions of the internal economies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.